Pulmonary, Critical Care, and Sleep Medicine

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

   Rochester, Minn.

   The purpose of this study is to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID.

   There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID.

2. ARrest RESpiraTory Failure From PNEUMONIA

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.

3. In-home Versus In-Clinic Subcutaneous Nivolumab Administration through Connected and Remote Cancer CARE Beyond Walls

   Jacksonville, Fla.

   The purpose of this study is to evaluate the impact of the location of SQ Nivo administration, at the infusion center or in the home, on patient preference and acceptability, safety, patient reported outcomes (PROs), and clinical outcomes.

4. A Study to Evaluate the Effectiveness of Psychological Support Based on Positive Suggestions on Mental Health Morbidity and Cognitive Function

   Rochester, Minn.

   The purpose of this trial is to compare the effectiveness of psychological support based on positive suggestions (PSBPS) vs. usual care on mental health morbidity and cognitive function in survivors of critical illness.

5. REstrictive versus LIberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI)

   Rochester, Minn.

   The objective of this study is to evaluate the feasibility of alternative Net Ultrafiltration (UFNET) rate strategies among critically ill adults with acute kidney injury (AKI) and treated with Continuous Kidney Replacement Therapy (CKRT).

    

6. A Study to Identify Discomforts Among Intensive Care Unit Patients

   Rochester, Minn.

   The primary purpose of this study is to assess and describe the contributing sources of discomfort(s) experienced by ICU patients utilizing the Discomforts Perceived by ICU Patients instrument, a modified version of the Inconforts des Patients de REAnimation questionnaire (IPREA).

7. A Study to Evaluate Progenitor Cells for Patients with Degenerative Lung Disease

   Rochester, Minn.

   The purpose of this study is to use a patient's own cells to fabricate a recellularized scaffold to repopulate the lung and restore function that could offer a solution for patients with degenerative lung disease.

8. Analysis of the Cardiac, Aorta and Carotid Artery Walls for Hemodynamic Monitoring in the Intensive Care Unit

   Jacksonville, Fla.

   The primary aim of this study is to determine if biomechanical properties of cardiac and large arterial walls measured by ultrasound-based novel imaging technology correlate with hemodynamic parameters measured by other tools in the ICU.

9. A Study to Evaluate the Effectiveness and Safety of RalinEpag for Improving Treatment Outcomes in PAH Patients

   Jacksonville, Fla.

   The purpose of this study is to demonstrate the effect of ralinepag the time to first adjudicated clinical worsening event in subjects with pulmonary arterial hypertension (PAH).Clinical worsening event is defined as 1 of the following: death, nonelective hospital admission of <24 hours due to worsening PAH or RHF, initiation of parenteral or inhaled therapy, disease progression, or unsatisfactory long term clinical response.

10. Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery (DISCOVERY)

    Rochester, Minn.

    The purpose o fthis study

    A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset.

    All participants will undergo baseline screening for evidence of pre-stroke dementia. Those who pass baseline screening will complete a blood draw and a series of cognitive and functional assessments at baseline.

    Participants will undergo in-person (3-6 months, 18 months) and telephone (annual) follow-up visits for the duration of the study to assess for longitudinal cognitive and functional outcomes. In addition to Tier 1 procedures, at each in-person follow-up visit: Tier 2 participants will also undergo MRI scanning, comprehensive cognitive assessment batteries and longitudinal blood collection; and Tier 3 participants will also complete amyloid- and tau-PET/CT scans.